Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580305 · ClinicalTrials.gov registry record · Phase 2
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
A Phase 2 study, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 564
- Enrollment target
NCT02580305 is a Phase 2 study that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 564 participants.
The verdict
NCT02580305, a Phase 2 study, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 564 participants
- Enrollment target
Study Summary
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and memantine HCl.
Interventions
- DRUG Placebo
- DRUG Memantine
- DRUG Donepezil
- DRUG SUVN-502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02580305
The ClinicalTrials.gov registry entry for NCT02580305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02580305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02580305 about?
NCT02580305 is a clinical study titled "SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study". This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and ...
What is the current status of trial NCT02580305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 564 participants. The study started on 2015-09. Estimated completion is 2019-11-07.
What interventions are being tested in trial NCT02580305?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG), Donepezil (DRUG), SUVN-502 (DRUG).
Who is sponsoring clinical trial NCT02580305?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.